title: Prevention of intraperitoneal adhesions and abscesses by polysaccharides isolated from Phellinus spp in a rat peritonitis model.
abstract: OBJECTIVE
  To assess whether polysaccharides isolated from fungi, Phellinus spp, could reduce the adhesion and abscess formation in a rat peritonitis model.
  
  
  BACKGROUND
  Although polysaccharides from Phellinus spp is a well-known material with antiinflammatory properties, little is known regarding its ability to prevent intraperitoneal adhesions. We have assessed the adhesion- and abscess-reducing effect of polysaccharides from Phellinus gilvus (PG) and Phellinus linteus (PL) in a rat peritonitis model.
  
  
  METHODS
  In 60 SD rats, experimental peritonitis was induced using the cecal ligation and puncture model (CLP). Animals were randomly assigned to 5 groups; ringer lactate solution (RL group), polysaccharides from PG and PL (PG and PL group), hyaluronic acid (HA group), and carboxymethylcellulose (CMC group). Intraperitoneal adhesions and abscesses were noted at 7 day after CLP. RT-PCR assay for urokinase-type plasminogen activator (uPA), its cellular receptor (uPAR), tissue-type plasminogen activator (tPA), plasminogen activator inhibitor type 1 (PAI-1), and tumor necrosis factor (TNF)- alpha was performed to assess the cecal tissue.
  
  
  RESULTS
  Adhesion formation was significantly reduced in PG, PL, CMC, and HA groups (P < 0.001) compared with that in RL group. The incidence of abscesses was also significantly reduced in PG and PL groups (P < 0.05) compared with that in the RL group. The level of uPA, uPAR, tPA, and TNF-alpha was highly expressed in PG and PL group, as compared with the RL group.
  
  
  CONCLUSIONS
  We concluded that PG and PL had significant adhesion- and abscess-reducing effects and may act by modulating fibrinolytic capacity of uPA and/or tPA produced from macrophages in a rat peritonitis model.
authors.affiliation: Department of Surgery, College of Veterinary Medicine, Kangwon National University, Chunchon, Korea.
authors.forename: Jae-Sung
authors.initials: JS
authors.lastname: Bae
authors.forename: So-Jeo
authors.initials: SJ
authors.lastname: Ahn
authors.forename: Hyunee
authors.initials: H
authors.lastname: Yim
authors.forename: Kwang-Ho
authors.initials: KH
authors.lastname: Jang
authors.forename: Hee Kyung
authors.initials: HK
authors.lastname: Jin
mesh_terms: D018784:Abdominal Abscess / Q000209:etiology / Q000382:microbiology / Q000517:prevention & control*; D000818:Animals; D001202:Ascitic Fluid / Q000382:microbiology; D001487:Basidiomycota; D002266:Carboxymethylcellulose Sodium / Q000627:therapeutic use; D002432:Cecum / Q000737:chemistry; D006820:Hyaluronic Acid / Q000627:therapeutic use; D008297:Male; D010538:Peritonitis / Q000150:complications* / Q000378:metabolism / Q000382:microbiology; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis; D011134:Polysaccharides / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011956:Receptors, Cell Surface / Q000032:analysis; D055293:Receptors, Urokinase Plasminogen Activator; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000267:Tissue Adhesions / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D010959:Tissue Plasminogen Activator / Q000032:analysis; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis
chemical_list: D017395:Plasminogen Activator Inhibitor 1; C524900:Plaur protein, rat; D011134:Polysaccharides; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D014409:Tumor Necrosis Factor-alpha; D006820:Hyaluronic Acid; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; D002266:Carboxymethylcellulose Sodium
references.citation: Eur J Surg. 1999 Nov;165(11):1012-9
references.pmid: 10595602
references.citation: J Vet Med Sci. 2004 Oct;66(10):1205-11
references.pmid: 15528850
references.citation: J Surg Res. 2001 Dec;101(2):248-53
references.pmid: 11735283
references.citation: Biochem Soc Trans. 2002 Apr;30(2):126-31
references.pmid: 12023839
references.citation: Am J Surg. 2003 Apr;185(4):339-43
references.pmid: 12657386
references.citation: Biol Pharm Bull. 2003 Jun;26(6):823-31
references.pmid: 12808294
references.citation: Biol Pharm Bull. 2003 Oct;26(10):1418-23
references.pmid: 14519947
references.citation: Biotechnol Lett. 2004 Jan;26(1):31-3
references.pmid: 15005148
references.citation: J Surg Res. 1980 Aug;29(2):189-201
references.pmid: 6997619
references.citation: J Exp Med. 1991 Jun 1;173(6):1511-20
references.pmid: 1851799
references.citation: Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir. 1990;:1009-16
references.pmid: 1983476
references.citation: J Am Coll Cardiol. 1992 May;19(6):1350-9
references.pmid: 1342779
references.citation: Int J Immunopharmacol. 1992 Nov;14(8):1363-73
references.pmid: 1334474
references.citation: J Surg Res. 1995 Dec;59(6):759-63
references.pmid: 8538178
references.citation: J Surg Res. 1995 Dec;59(6):764-71
references.pmid: 8538179
references.citation: Eur J Surg. 1997 Mar;163(3):169-74
references.pmid: 9085057
references.citation: Surg Clin North Am. 1997 Jun;77(3):671-88
references.pmid: 9194886
references.citation: Br J Plast Surg. 1997 Jul;50(5):362-8
references.pmid: 9245871
references.citation: Surgery. 1999 Feb;125(2):211-6
references.pmid: 10026756
references.citation: Immunopharmacology. 1999 Feb;41(2):157-64
references.pmid: 10102797
references.citation: Hum Reprod. 1999 Jun;14(6):1470-2
references.pmid: 10357961
references.citation: Arch Surg. 2001 Mar;136(3):291-6
references.pmid: 11231848